REQUEST A DEMO
Total
USD $0.00
Search more companies

UAB Bioversija (Lithuania)

Main Activities: Other Chemical and Allied Products Merchant Wholesalers | Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: Research and Development in Nanotechnology
Full name: UAB Bioversija Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

UAB Bioversija is a company based in Lithuania, with its head office in Vilnius. It operates in the Other Chemical and Allied Products Merchant Wholesalers sector. The company was established on December 17, 2008. UAB Bioversija currently employs 13 (2025) people. In 2024, the company reported a net sales revenue increase of 17.22%. UAB Bioversija’s net profit margin increased by 4.11% in 2024.

Headquarters
Akademijos g. 7
Vilnius; Vilnius county; Postal Code: LT-08412

Contact Details: Purchase the UAB Bioversija report to view the information.

Basic Information
Total Employees:
Purchase the UAB Bioversija report to view the information.
Registered Capital:
Purchase the UAB Bioversija report to view the information.
Financial Auditors:
Purchase the UAB Bioversija report to view the information.
Incorporation Date:
December 17, 2008
Key Executives
Purchase this report to view the information.
Director
Company Performance
Financial values in the chart are available after UAB Bioversija report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
17.22%
Total operating revenue
17.22%
Net Profit (Loss) for the Period
42.81%
Total equity
26.58%
Net Profit Margin
4.11%
Return on Equity (ROE)
2.57%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?